<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033630</url>
  </required_header>
  <id_info>
    <org_study_id>CRE2005123T</org_study_id>
    <nct_id>NCT01033630</nct_id>
  </id_info>
  <brief_title>Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen</brief_title>
  <official_title>A Novel Randomized Double-Blind Placebo-Control Clinical Trial in High-Risk Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atherosclerosis (in particular stroke and heart attack) is the most important health issue in
      modernized society and high blood pressure is an important predisposing factor. Hypertensive
      subjects with other chronic disease such as diabetes mellitus or impaired renal function are
      particularly vulnerable to these atherosclerotic complications in spite of standard
      antihypertensive therapies.

      Danshen and Gegen are commonly used in Chinese materia medica as treatment for cardiac
      symptoms and atherosclerosis-related disorders.

      The objective of this study is to test Danshen and Gegen as an cardiovascular-protective
      adjunctive regimen to prevent high-risk hypertensive cohort from primary atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Danshen and Gegen (D&amp;G) are two traditional herbal medicines used for cardiac symptoms in
      ancient Chinese medicinal literature. Recent studies suggest their therapeutic effects in
      blood pressure and lipid-lowering, anti-oxidation, microcirculation-promoting, foam
      cells-modulation and have beneficial effects on atherogenic process in coronary patients.

      To evaluate the potential of D&amp;G in primary atherosclerosis prevention in high risk
      hypertension. Patients with high risk hypertension associated with left ventricular
      hypertrophy, diabetes mellitus and renal insufficiency were randomized to receive D&amp;G herbal
      capsules (2gm/day), or (1gm/day) or identical placebo capsules in double-blind and parallel
      fashion for 12 months on top of their anti-hypertensive treatments. Flow-mediated dilation
      (endothelium-dependent dilation, FMD) and nitroglycerin-induced dilation
      (endothelium-independent dilation, NTG) of brachial artery, and carotid intima-media
      thickness (surrogate atherosclerosis marker, IMT) were measured by high resolution B-mode
      ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound study for measuring carotid intima-media thickening (IMT)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood tests: lipids, creatinine, glucose, fibrinogen, hs-CRP and haemoglobin A1-C Physical examination: Blood pressure, weight, height, body mass index, hip waist ratio</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Image-matched placebo of active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D&amp;G 1g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly allocated into three groups, D&amp;G capsule 1g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D&amp;G 2g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomly allocated into three groups, D&amp;G capsule 2g/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D&amp;G 2g</intervention_name>
    <description>Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day</description>
    <arm_group_label>D&amp;G 2g</arm_group_label>
    <other_name>Danshen Gegen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D&amp;G 1g</intervention_name>
    <description>Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day</description>
    <arm_group_label>D&amp;G 1g</arm_group_label>
    <other_name>Danshen Gegen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Image-matched placebo, made with starch.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-risk hypertension: Asymptomatic hypertensive (pretreatment BP&gt;160/95mmHg)
             subjects, currently blood pressure under control (BP&lt;140/90mmHg),

          -  Aged 35-70 years

          -  With either (i)left ventricular hypertrophy on ECG or echocardiographic criteria, (ii)
             diabetes mellitus, or (iii) mild renal impairment (plasma creatinine 120-250Âµmol/l)

        Exclusion Criteria:

          -  Known intolerance to D&amp;G due to adverse effect, patients with bleeding, disorders or
             on long-term anticoagulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas YK Chan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine &amp; Therapeutics, Prince of Wales hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alice Ho Miu Ling Nethersole Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yan Chai Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997 Sep 2;96(5):1432-7.</citation>
    <PMID>9315528</PMID>
  </reference>
  <reference>
    <citation>O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999 Jan 7;340(1):14-22.</citation>
    <PMID>9878640</PMID>
  </reference>
  <reference>
    <citation>Woo KS, Chook P, Raitakari OT, McQuillan B, Feng JZ, Celermajer DS. Westernization of Chinese adults and increased subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2487-93.</citation>
    <PMID>10521379</PMID>
  </reference>
  <reference>
    <citation>Sieveking DP, Woo KS, Fung KP, Lundman P, Nakhla S, Celermajer DS. Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro. Int J Cardiol. 2005 Oct 20;105(1):40-5.</citation>
    <PMID>16207543</PMID>
  </reference>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Thomas Yan Keung Chan</name_title>
    <organization>Department of Medicine and Therapeutics, The Chinese University of Hong Kong</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

